论文部分内容阅读
1988年作者曾报道Simvastation(SIM)可降低与肾病综合征有关的高血脂症。其效果优于消胆胺并且患者能较好地耐受。作者以前曾对8例患者进行研究,其中7例长期用SIM(40mgl天1次)治疗,另一患者因开始用环孢菌素A而中止服SLM。此7例中男性6例平均年龄57(45～77)岁,活检证实其中膜性肾小球肾炎4例,局灶性肾小球硬化症2例,系膜毛细血管性肾小球肾炎1例。患者均未用类固
In 1988, authors reported that Simvastation (SIM) reduces hyperlipidemia associated with nephrotic syndrome. Its effect is superior to cholestyramine and the patient is well tolerated. The authors previously conducted a study of 8 patients, 7 of whom were treated with SIM (40 mg once daily) for a prolonged period of time and the other patient discontinued SLM due to the start of cyclosporin A. The average age of 6 males in these 7 cases was 57 (45-77) years. Biopsy confirmed 4 cases of membranous glomerulonephritis, 2 cases of focal glomerulosclerosis, 1 cases of mesangial capillary glomerulonephritis 1 example. None of the patients had a solidoid